and Gang Shen

Dr. and Gang Shen


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
TWTong-Bing Wang
Tong-Bing Wang
MGMei Geng
Mei Geng
HJHua Jin
Hua Jin
ATAi-Guo Tang
Ai-Guo Tang
HSHao Sun
Hao Sun
QSQiang Sun
Qiang Sun
Renal cell carcinoma (RCC) cells have increased lipogenesis and cholesterol synthesis. Sterol regulatory element-binding protein-1 (SREBP1) is cleaved by site 1 protease (S1P) to release the transcriptionally active amino-terminal domain. PF-429242 is a potent and competitive S1P inhibitor. We here tested its activity in RCC cells. In established and primary human RCC cells, PF-429242 potently inhibited cell proliferation, migration, and invasion. The S1P inhibitor provoked apoptosis activation in RCC cells. Furthermore, shRNA-mediated S1P silencing or CRISPR/Cas9-induced S1P knockout led to RCC cell growth inhibition and apoptosis activation. Conversely, ectopic overexpression of SREBP1 or S1P augmented RCC cell proliferation and migration. Daily i.v. injection of a single dose of PF-429242 robustly inhibited RCC xenograft growth in severe combined immunodeficiency mice. Additionally, intratumoral injection of S1P shRNA lentivirus inhibited RCC xenograft growth in mice. SREBP1, S1P, and its target gene low density lipoprotein receptor (LDLR) were significantly elevated in human RCC tissues. These results suggest that targeting S1P by PF-429242 inhibited RCC cell growth in vitro and in vivo.

21 August 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LJLu Jin
Lu Jin
JZJin Zhu
Jin Zhu
LYLinya Yao
Linya Yao
ASand Gang Shen
and Gang Shen
BXBoxin Xue
Boxin Xue
WTWei Tao
Wei Tao
Sphingosine kinases (SphK), including SphK1 and SphK2, are important enzymes promoting progression of prostate cancer. SKI-178 is a novel and highly potent SphK1/2 dual inhibitor. We here tested the potential anti-prostate cancer cell activity of SKI-178. Bioinformatics analyses and results from local tissues demonstrated that that both SphK1 and SphK2 are upregulated in human prostate cancer tissues. Ectopic overexpression of SphK1 and SphK2, by lentiviral constructs, promoted primary prostate cancer cell proliferation and migration. In primary human prostate cancer cells and immortalized cell lines, SKI-178 potently inhibited cell viability, proliferation, cell cycle progression and cell migration, causing robust cell death and apoptosis. SKI-178 impaired mitochondrial functions, causing mitochondrial depolarization, reactive oxygen species production and ATP depletion.SKI-178 potently inhibited SphK activity and induced ceramide production, without affecting SphK1/2 expression in prostate cancer cells. Further, SKI-178 inhibited Akt-mTOR activation and induced JNK activation in prostate cancer cells. Contrarily, a constitutively-active Akt1 construct or the pharmacological JNK inhibitors attenuated SKI-178-induced cytotoxicity in prostate cancer cells. In vivo, daily intraperitoneal injection of a single dose of SKI-178 potently inhibited PC-3 xenograft growth in nude mice. SphK inhibition, ceramide production, ATP depletion and lipid peroxidation as well as Akt-mTOR inactivation and JNK activation were detected in PC-3 xenograft tissues with SKI-178 administration. Together, targeting SphK1/2 by SKI-178 potently inhibited prostate cancer cell growth in vitro and in vivo.

1 February 2023 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
JLJie Luo
Jie Luo
ZMZhijun Miao
Zhijun Miao
XHXinglong Huang
Xinglong Huang
YYYifan Yang
Yifan Yang
MLMing Liu
Ming Liu
Tao YangTao Yang
Tao Yang
It still remains a great challenge to efficiently treat malignant cancers which severely threaten human health. Photodynamic therapy (PDT) as a localized therapeutic modality has improved the therapeutic efficacy via chemical damage through reactive oxygen species (ROS). However, their efficacy is severely hampered by insufficient targeted delivery of photosensitizers owing to the lack of suitable carrier with facile preparation process and the clinical applicability. Herein, we applied clinically approved human serum albumin as the nanoreactor to encapsulate photosensitizers Chlorin e6 (Ce6) for enhancing their tumor accumulation and subsequently potent PDT effect against bladder cancer models. Albumin-loaded Chlorin e6 nanoparticles (CA-NPs) with rational nanoscale size exhibit increased reactive oxygen species production and excellent resistance to photobleaching. Moreover, CA-NPs could be efficiently internalized by tumor cells and locate in the lysosome, while they rapidly translocate to cytosol after irradiation to induce remarkable cytotoxicity (IC50 ∼5.8 μg/ml). Furthermore, CA-NPs accumulate effectively in tumor tissue to afford total eradication of murine bladder tumor after single injection. More importantly, we also evidence the superior PDT effect in fresh human bladder tumor tissues via abundant reactive oxygen species generation and subsequent cell apoptosis. These findings demonstrate that human serum albumin acts as a universal tool to load small organic photoactivatable molecule with remarkable effectiveness and readiness for clinical translation.

17 September 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ZMZhijun Miao
Zhijun Miao
XSXue Song
Xue Song
安徐安安 徐
安安 徐
CYChang Yao
Chang Yao
PLPeng Li
Peng Li
ASand Gang Shen
and Gang Shen
Background: Activating the cytosolic innate immune sensor, the cGAS-STING pathway, holds great promise for enhancing antitumor immunity, particularly in combination with immune checkpoint inhibitors (ICIs). However, the clinical application of STING agonists is often hindered by poor tumor accumulation, limited cellular uptake, and rapid clearance. To address these challenges, we developed a human serum albumin (HSA)-based nanoreactor system for the efficient delivery of the STING agonist SR-717, aiming to improve its antitumor efficacy. Methods: Using a biomineralization technique, we encapsulated SR-717 within HSA nanocages to form SH-NPs. These nanoparticles were characterized in terms of size, stability, and cellular uptake, and their ability to activate the STING pathway was assessed in both in vitro and in vivo models, including freshly isolated human renal tumor tissues. In vivo antitumor efficacy was evaluated in a murine renal tumor model, and immune responses were measured. Results: SH-NPs exhibited enhanced stability, efficient cellular uptake, and superior tumor accumulation compared to free SR-717. They robustly activated the STING pathway, as evidenced by increased phosphorylation of TBK1 and IRF3, along with elevated IFN-β production. Additionally, SH-NPs reshaped the immunosuppressive tumor microenvironment, promoting T-cell-mediated immunity and improving the therapeutic efficacy of checkpoint blockade in murine models. The validation in human renal tumor tissues further highlighted their potential for clinical translation. Importantly, SH-NPs were well tolerated with minimal systemic toxicity. Conclusions: This study underscores the potential of HSA-based nanoparticles for the targeted delivery of STING agonists, effectively enhancing antitumor immunity and improving cancer immunotherapy outcomes. SH-NPs offer a promising solution to the limitations of current STING agonists in clinical settings.

16 June 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
LDLirong Duan
Lirong Duan
JWJing Wang
Jing Wang
ZMZhijun Miao
Zhijun Miao
DZDulin Zuo
Dulin Zuo
WSWeiwei Sun
Weiwei Sun
GLGang Li
Gang Li

1 September 2025 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
PLPeng Li
Peng Li
YXYing Xu
Ying Xu
SYShijie Yu
Shijie Yu
ZMZhijun Miao
Zhijun Miao
HXHongbo Xu
Hongbo Xu
ASand Gang Shen
and Gang Shen
Background: Prostate cancer (PCa) precise surgical resection remains a critical challenge due to positive margins compromising outcomes. This study sought to explore the safety and efficacy of DGPR1008, a novel near-infrared (NIR) prostate-specific membrane antigen (PSMA)-targeted fluorescent contrast agent, in fluorescence-guided surgery (FGS) of PCa. Methods: This single-center, open-label, prospective, single-arm, exploratory study was carried out in The Fourth Affiliated Hospital of Soochow University, China. Patients newly diagnosed with PCa (a Gleason score ≥7) were eligible for enrollment. All patients underwent laparoscopic radical prostatectomy (LRP) with pelvic lymph node dissection (PLND) using DGPR1008. Four dose cohorts were studied: dose cohort A, which received 0.06 mg/kg of DGPR1008 24 h preoperatively; dose cohort B, which received 0.03 mg/kg of DGPR1008 24 h preoperatively; dose cohort C, which received 0.03 mg/kg of DGPR1008 12 h preoperatively, and dose cohort D, which received 0.045 mg/kg of DGPR1008 24 h preoperatively. Safety and efficacy were assessed. Results: From July, 2023 to January, 2024, 14 eligible patients were included in the study. In total, 32 adverse events (AEs) were observed. One patient (7.1%) presented with four serious adverse events (SAEs), including urinary fistula, infected lymphocele, wound complications, and acute exacerbation of chronic obstructive pulmonary disease. None of the AEs or SAEs was found to be associated with the administration of DGPR1008. Compared with the other dose cohorts, DGPR1008 showed the highest sensitivity (80.6%) for detecting PCa in vivo in dose cohort B. Further, dose cohort B provided the highest target-to-background ratio (TBR) through all phases of tumor imaging, both in vivo and ex vivo, on the gross and fixed tissue. DGPR1008 enabled the real-time visualization of tumor-positive surgical margins, and had a sensitivity of 90% in vivo and 100% ex vivo. Conclusions: DGPR1008 is safe and well tolerated, and may be used in the intraoperative identification of primary PCa and positive surgical margins. Dose cohort B (0.03 mg/kg, 24 h preoperatively) is optimal for efficacy and TBR.